VLG vs. BXP, ANCR, STX, EAH, DNL, PXS, MXC, CHLL, RGT, and CEL
Should you be buying Venture Life Group stock or one of its competitors? The main competitors of Venture Life Group include Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Shield Therapeutics (STX), ECO Animal Health Group (EAH), Diurnal Group (DNL), Provexis (PXS), Argent BioPharma (MXC), Chill Brands Group (CHLL), Argent BioPharma (RGT), and Celadon Pharmaceuticals (CEL). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Venture Life Group vs. Its Competitors
Beximco Pharmaceuticals (LON:BXP) and Venture Life Group (LON:VLG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.
Beximco Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Venture Life Group has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.
Beximco Pharmaceuticals has higher revenue and earnings than Venture Life Group. Venture Life Group is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Beximco Pharmaceuticals and Beximco Pharmaceuticals both had 1 articles in the media. Beximco Pharmaceuticals' average media sentiment score of 0.75 beat Venture Life Group's score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the media.
1.2% of Beximco Pharmaceuticals shares are held by institutional investors. Comparatively, 37.4% of Venture Life Group shares are held by institutional investors. 4.2% of Beximco Pharmaceuticals shares are held by company insiders. Comparatively, 6.8% of Venture Life Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Beximco Pharmaceuticals has a net margin of 13.71% compared to Venture Life Group's net margin of 1.44%. Beximco Pharmaceuticals' return on equity of 13.12% beat Venture Life Group's return on equity.
Summary
Beximco Pharmaceuticals beats Venture Life Group on 9 of the 12 factors compared between the two stocks.
Get Venture Life Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for VLG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Venture Life Group Competitors List
Related Companies and Tools
This page (LON:VLG) was last updated on 9/13/2025 by MarketBeat.com Staff
Free VLG Stock Alerts